Is CSTL above its 150-day moving average?

CSTL is currently below its 150-day moving average by 31.10%. The MA150 sits at $30.86.

What is CSTL's RSI right now?

CSTL's 14-period RSI is 48.3. This is in a neutral zone (30–70).

Is CSTL's MACD bullish or bearish?

CSTL's MACD histogram reads +0.2307. A positive histogram means short-term momentum is leaning bullish.

How are CSTL's technical signals calculated?

Scanance computes CSTL's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

CS

Castle Biosciences, Inc.

CSTLHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot

MA150-31.10%

$30.86

Price below medium-term moving average.

MA200-25.96%

$28.72

Below long-term trend line.

RSI-14neutral

48.3

Balanced. Not overbought, not oversold.

MACDpositive

+0.2307

Histogram positive — upward momentum.

Financials · Annual

Revenue

$344.2M

+3.7% YoY

Net Income

-$24.2M

-232.4% YoY

EBITDA

$11.3M

-70.3% YoY

Free Cash Flow

$12.9M

Scan Results

Daily timeframe

DateIndicatorDetails

About Castle Biosciences, Inc.

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal. Valued at $644.8M, CSTL is a small-cap name in its sector. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.

Key stats

Market Cap$644.8M

Fwd P/E-23.59

EPS$-0.42

Beta1.11

52W Change+33.3%

ROE-2.9%

Analysis

Castle Biosciences, Inc. holds $261.7M in cash against $36.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $12.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -2.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $137.0M (2022) to $344.2M (2025), reflecting a 151% increase over the period.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Castle Biosciences, Inc.'s trajectory.

Links

Company website ↗

Castle Biosciences, Inc.

News & analytics is part of Premium.

Technical readouts are part of Premium.